Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …

Background For patients receiving therapy with oral anticoagulants (OACs), the proportion of
time spent in the therapeutic range (ie, anticoagulation control) is strongly associated with …

Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin
in patients with venous thromboembolism is unclear. Methods In a randomized, double …

Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation and
treatment of venous thromboembolism, but little is known about rivaroxaban-related …

This article concerning the pharmacokinetics and pharmacodynamics of vitamin K
antagonists (VKAs) is part of the American College of Chest Physicians Evidence-Based …

BACKGROUND: Atrial fibrillation (AF) affects a significant proportion of the American
population and increases ischemic stroke risk by 4-to 5-fold. Oral vitamin K antagonists …

Objectives: This study was designed to determine whether genotype testing for patients
initiating warfarin treatment will reduce the incidence of hospitalizations, including those due …

Background Venous thromboembolism (VTE) is a serious complication. Large claims
databases can potentially identify the effects that medications have on VTE. The purpose of …

Healthcare reform is upon the United States (US) healthcare system. Prioritisation of
preventative efforts will guide necessary transitions within the US healthcare system. While …

The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ROCKET AF needs to be confirmed in daily care. To evaluate effectiveness …